ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,223.59
0.83%
Dow Jones
40,287.53
0.00%
Gold vs US Dollar
2,396.19
-0.19%
Brent Oil
81.43
-1.03%
Bitcoin
67,630.95
-0.77%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Germany
  5. TG

  6. BioNTech SE (22UA) Share Price

22UA BioNTech SE

79.20
0.65 (0.83%)
13:22:11 - Realtime Data
 Name  Symbol  Market  Type  ISIN  Description 
 BioNTech SE TG:22UA Tradegate (DE) Ordinary Share  Adr
     Change  % Chg  Cur  Bid  Offer  High  Low  Open  Volume  Chg Time  RN  NRN 
   0.65 0.83 79.20 79.20 79.45 79.55 78.15 78.2 14,889 12:22:11   
 Type  Size  Price  Time  Units 
  36 79.20 12:23:07 EUR
 
Recent News
DateTimeSource
HeadlineMore 22UA News
22/07/202411:45UKREGBioNTech veröffentlicht am 5. August 2024 Ergebnisse für das zweite Quartal 2024 und informiert über operativen Fortschritt
22/07/202411:45UKREGBioNTech to Report Second Quarter 2024 Financial Results and Corporate Update on August 5, 2024
27/06/202415:30GLOBEPfizer und BioNTech erhalten positive CHMP-Empfehlung für an Omikron JN.1 angepassten COVID-19-Impfstoff in der Europäischen Union
27/06/202415:30GLOBEPfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union  
24/06/202411:45GLOBEBioNTech und DualityBio erhalten Fast-Track-Status der FDA für Antikörper-Wirkstoff-Konjugat-Kandidat BNT324/DB-1311 bei Prostatakrebs
24/06/202411:45GLOBEBioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug Conjugate Candidate BNT324/DB-1311 in Prostate Cancer
01/06/202415:00GLOBEInvestigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
Period
Draw mode
Data Downloads for 22UA

Export historical price information open, high, low, close, volume (OHLCV) to Excel

Intraday price data (2 weeks, 1 minute bars)


Loading Follow Feed...

Latest BioNTech SE Articles